Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience

G. Bonadonna; A. Santoro; A. M. Gianni; S. Viviani; S. Siena; M. Bregni; R. Zucali; F. Lombardi; V. Bonfante; L. Gianni; P. Valagussa

Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience

G. Bonadonna, A. Santoro, A. M. Gianni, S. Viviani, S. Siena, M. Bregni, R. Zucali, F. Lombardi, V. Bonfante, L. Gianni, P. Valagussa

Research output: Contribution to journal › Article › peer-review

Abstract

This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

Original language	English
Pages (from-to)	9-16
Number of pages	8
Journal	Annals of Oncology
Volume	2
Issue number	SUPPL. 1
Publication status	Published - 1991

ASJC Scopus subject areas

Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience'. Together they form a unique fingerprint.

Cite this

Primary and salvage chemotherapy in advanced Hodgkin's disease : The Milan Cancer Institute experience. / Bonadonna, G.; Santoro, A.; Gianni, A. M.; Viviani, S.; Siena, S.; Bregni, M.; Zucali, R.; Lombardi, F.; Bonfante, V.; Gianni, L.; Valagussa, P.

In: Annals of Oncology, Vol. 2, No. SUPPL. 1, 1991, p. 9-16.

Research output: Contribution to journal › Article › peer-review

@article{441f4871f7534a519d0c12d717ef363b,

title = "Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience",

abstract = "This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.",

author = "G. Bonadonna and A. Santoro and Gianni, {A. M.} and S. Viviani and S. Siena and M. Bregni and R. Zucali and F. Lombardi and V. Bonfante and L. Gianni and P. Valagussa",

year = "1991",

language = "English",

volume = "2",

pages = "9--16",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Primary and salvage chemotherapy in advanced Hodgkin's disease

T2 - The Milan Cancer Institute experience

AU - Bonadonna, G.

AU - Santoro, A.

AU - Gianni, A. M.

AU - Viviani, S.

AU - Siena, S.

AU - Bregni, M.

AU - Zucali, R.

AU - Lombardi, F.

AU - Bonfante, V.

AU - Gianni, L.

AU - Valagussa, P.

PY - 1991

Y1 - 1991

N2 - This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

AB - This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026067722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026067722&partnerID=8YFLogxK

M3 - Article

C2 - 1710489

AN - SCOPUS:0026067722

VL - 2

SP - 9

EP - 16

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -